Addendum
Daratumumab (multiple myeloma) - Addendum to Commission A21-126
Report documents
-
Addendum
Daratumumab (multiple myeloma) - Addendum to Commission A21-126
Dossier assessment
Indication:
Adult patients with newly diagnosed multiple myeloma who cannot have autologous stem cell transplant
Result of dossier assessment:
Unchanged after addendum:
Hint of considerable added benefit
Additional information
Federal Joint Committee (G-BA)
2022-03-18 A G-BA decision was published.
Project details
- Project no.
- A22-27
- Commission
- Commission awarded on 08.02.2022 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Daratumumab (newly diagnosed multiple myeloma, unsuitable for stem cell transplantation) - Benefit assessment according to §35a Social Code Book V (new scientific findings)
Status: Commission completed